This summer, photos of New York covered by smoke spread widely catching global attention on the massive wildfires in Canadian forests that caused that apocalyptic scenario. But why should we as oncologists be concerned about such events?
Molecular characterisation of tumour subtypes and immunotherapy are key areas attracting researchers’ efforts that may shape the future of clinical practice, according to ESMO President Prof. Andrés Cervantes
Recent findings from studies confirm the promises of ctDNA in this setting, but unanswered questions still remain about timing and methodology
An ESMO study shows that precision oncology is out of reach for the majority of patients, with costs of technologies and reimbursement policies acting as major barriers
Tumour agnostic targeted agents and ‘smarter’ dynamic designs are two major areas of interest leading to more patient-centric approaches in cancer care
Tools and targeted communication are needed to guide clinical practice and help healthcare professionals make sustainable choices
Dr Raffaella Casolino is the third ESMO young medical oncologist serving as a cancer expert on the WHO Cancer Control team
Adding precision to dose-finding in early-phase clinical trials has become critical in the immunotherapy era, and moving away from paradigms of the past has become mandatory